LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the management team will be attending the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022, in Barcelona, Spain. ATTD is a scientific conference that was established in 2008. The meetings at the conference have become the most renowned forum worldwide for presenting developments in new diabetes technologies and treatments.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said, “This annual conference is where clinicians, diabetes care providers, researchers, industry leaders and investors come together to share knowledge and develop collaborations. As we continue to broaden our product portfolio, the development of a treatment for Type 1 and insulin-dependent Type 2 diabetes that can essentially serve as an ‘artificial pancreas’ is vitally important to PharmaCyte. Our live-cell encapsulation-based treatment offers real hope for future development in the field of diabetes.”
Main topics being discussed during the conference include decision support systems, data and artificial intelligence based decision support systems, closed-loop systems and algorithms, artificial pancreas, insulin pumps, glucose sensors, implantable pumps and sensors, new insulin analogs and new insulin delivery systems, devices focused on diabetic preventions, informatics in the service of medicine; telemedicine, software and other technologies, advanced medical technologies to be used in hospitals and more.
In addition to attending presentations and discussions by distinguished professionals in the field, PharmaCyte’s management team will meet with members of its International Diabetes Consortium to launch its new diabetes endeavors.
To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: https://pharmacyte.com/Cancer
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. The encapsulation of the cell line will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a “bio-artificial pancreas” for purposes of insulin production.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward- looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005443/en/
Dr. Gerald W. Crabtree
PharmaCyte Biotech, Inc.
Investor Relations Department
Email: [email protected]
Source: PharmaCyte Biotech, Inc.
Released April 27, 2022